Prediction of survival in patients with Stage IV kidney cancer

• Main Authors: L. V. Mirilenko, A. B. Poluyanchik
• Format: Article
• Language: Russian
• Published: ABV-press 2015-03-01
• Series: Onkourologiâ
• Subjects: kidney cancer; renal cell carcinoma; prognostic factors; risk groups; metastases; stage v kidney cancer; lymph nodes; differentiation grade; median survival; multidimensional mathematical model; adjusted survival
• Online Access: https://oncourology.abvpress.ru/oncur/article/view/415

The efficiency of treatment was evaluated and the predictors of adjusted survival (AS) were identified in patients with disseminated kidney cancer treated at the Republican Research and Practical Center for Oncology and Medical Radiology in 1999 to 2011 (A.E. Okeanov, P.I. Moiseev, L.F. Levin. Malignant tumors in Belarus, 2001–2012. Edited by O.G. Sukonko). Seven factors (regional lymph node metastases; distant bone metastases; a high-grade tumor; sarcomatous tumor differentiation; hemoglobin levels of < 125 g/l in women and < 150 g/l in men; an erythrocyte sedimentation rate of 40 mm/h; palliative surgery) were found to have an independent, unfavorable impact on AS. A multidimensional model was built to define what risk group low (no more than 2 poor factors), moderate (3–4 poor factors), and high (more than 4 poor factors)) the patients with Stage IV kidney cancer belonged to. In these groups, the median survival was 34.7, 17.2, and 4.0 months and 3-year AS rates were 48.6, 24.6, and 3.2 %, respectively.